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RESEARCH
Factors associated with viral 
non-suppression among adolescents living 
with HIV in Cambodia: a cross-sectional study
Kolab Chhim1, Gitau Mburu2, Sovannary Tuot1, Ratana Sopha1, Vohith Khol3, Pheak Chhoun1 and Siyan Yi1,4,5* 
Abstract 
Background: Adolescents living with HIV on antiretroviral therapy (ART) have worse treatment adherence, viral sup-
pression, and mortality rates compared to adults. This study investigated factors associated with viral non-suppression 
among adolescents living with HIV in Cambodia.
Methods: A cross-sectional study was conducted in August 2016 among 328 adolescents living with HIV aged 
15–17 years who were randomly selected from 11 ART clinics in the capital city of Phnom Penh and 10 other prov-
inces. Clinical and immunological data, including CD4 count and viral load, were obtained from medical records at 
ART clinics. Adolescents were categorized as having achieved viral suppression if their latest viral load count was 
< 1000 ribonucleic acid (RNA) copies/mL. Multivariate logistic regression analysis was performed to identify factors 
independently associated with viral non-suppression.
Results: The mean age of the participants was 15.9 years (SD = 0.8), and 48.5% were female. Median duration on 
ART was 8.6 (interquartile range = 6.0–10.6) years. Of total, 76.8% of the participants had achieved viral suppression. 
After adjustment for other covariates, the likelihood of having viral non-suppression remained significantly lower 
among adolescents who were: older/aged 17 (AOR = 0.46, 95% CI 0.21–0.98), had been on ART for more than 9 years 
(AOR = 0.35, 95% CI 0.19–0.64), had most recent CD4 count of > 672 (AOR = 0.47, 95% CI 0.26–0.86), had a relative as 
the main daily caregiver (AOR = 0.37, 95% CI 0.17–0.80), and did not believe that there is a cure for AIDS (AOR = 0.40, 
95% CI 0.21–0.75) compared to their reference group. The likelihood of having viral non-suppression also remained 
significantly higher among adolescents who had first viral load > 628 RNA copies/mL (AOR = 1.81, 95% CI 1.05–4.08) 
and among those who were receiving HIV care and treatment from an adult clinic (AOR = 2.95, 95% CI 1.56–5.59).
Conclusions: The proportion of adolescents living with HIV with viral suppression in this study was relatively high at 
76.8%, but falls short of the global target of 90%. Programs targeting younger adolescents and adolescents in transi-
tion from pediatric to adult care with a range of interventions including psychosocial support and treatment literacy 
could further improve viral suppression outcomes.
Keywords: Adolescents, Antiretroviral therapy (ART), HIV care and treatment, Viral suppression, Social determinants, 
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Background
Human immunodeficiency virus (HIV) is a leading cause 
of global burden of disease [1]. In recent years, significant 
progress has been made in increasing access to antiret-
roviral therapy (ART) for people living with HIV [2]. A 
key goal of ART is to suppress the replication of the virus. 
Suppressed viral replication facilitates restoration of the 
immune function and significantly reduces the risk of 
onward HIV transmission [3]. The World Health Organi-
zation (WHO) introduced viral load monitoring as a gold 
standard to follow up the treatment effectiveness in 2013 
[4], and Cambodia adopted these guidelines in late 2015 
[5]. The Cambodian national guidelines recommend that 
viral load testing be performed 6 months after ART ini-
tiation and repeated routinely once a year.
Despite the increasing access to ART, numerous studies 
have demonstrated suboptimal levels of viral suppression 
in different populations in many low-resource settings 
[1]. In particular, adolescents living with HIV tend to 
experience worse immunological and viral suppression 
outcomes compared to adults [6–9], which in turn con-
tributes to their higher mortality [10, 11]. Indeed, HIV‐
related deaths among adolescents have tripled since 2000, 
making HIV the second leading cause of death among 
adolescents globally [12]. While health related data for 
this age group remain scarce, there is emerging evidence 
indicating that adolescents living with HIV have been 
facing challenges in accessing HIV services [13].
Studies from different settings have identified a wide 
range of factors that may determine HIV treatment 
outcomes among adolescents. These factors include 
sub-optimal disclosure of adolescents’ HIV status [14, 
15], poor linkage to care [10], attrition from care and 
treatment [16], poor transition from pediatric to adult 
services [17], challenges with adherence to ART [18], 
economic hardships [19, 20], and AIDS-related stigma 
[15, 21]. These factors commonly prevent attainment of 
optimal ART outcomes among this young population.
In Cambodia, 8512 children and adolescents are liv-
ing with HIV and accessing care and treatment services 
from 37 ART clinics across the country [22]. Majority 
of them are infected through mother-to-child transmis-
sion [5]. According to the national guidelines,  children 
and adolescents up to the age of 15  are recommended 
to receive HIV care and treatment services from pediat-
ric ART clinics and to thereafter be transitioned to adult 
clinics. However, in practice, most adolescents living with 
HIV transition to adult care between 15 and 20 years of 
age [5]. Previous studies have indicated that, similar to 
the global situation, adolescents living with HIV in Cam-
bodia face challenges related to transitioning into adult 
services [23], AIDS-related stigma and issues of con-
fidentiality [24, 25], all of which affect HIV treatment 
outcomes. In addition, there is very limited information 
about viral suppression and its determinants among ado-
lescents living with HIV in Cambodia.
Given the above concerns and data gaps, the objec-
tive of this study is to determine the prevalence rate of 
viral suppression and factors associated with viral non-
suppression among adolescents living with HIV in Cam-
bodia. This information will be critical in identifying 
program interventions that can be further strengthened 
to optimize ART outcomes among this population in 
Cambodia and other resource-limited settings.
Methods
Study design and population
This cross-sectional study was conducted in August 2016 
as part of a larger study exploring challenges in transi-
tion into adult care among adolescents living with HIV 
in the capital city of Phnom Penh and 10 other  prov-
inces. Details of this study have been reported else-
where [20, 26]. A structured questionnaire was used for 
face-to-face interviews complemented by routine clini-
cal data retrieved from medical records in ART clinics. 
The study participants included adolescents living with 
HIV aged 15–17, who were receiving HIV care and treat-
ment services from 11 ART clinics. In 2016, the number 
of adolescents living with HIV in 18 clinics represented 
approximately 90% of the total number of adolescents 
living with HIV in the country. The remaining 10% 
were distributed across 21 sites, each with less than 10 
adolescents.
Participants were selected in three stages. First, a two-
stage cluster sampling method was used to select clusters 
to sample participants from the selected clinics, using a 
methodology developed by the WHO [27]. A compre-
hensive list of all ART clinics in the country with adoles-
cents living with HIV population estimates was created 
and used to select the clusters after excluding ART clin-
ics with less than 10 adolescents. This left a universe of 
598 adolescents receiving care and treatment from the 18 
major ART clinics. To minimize costs of data collection, 
additional seven clinics with less than 20 adolescent cli-
ents aged 15–17 were excluded.
Second, the required sample size was determined tak-
ing into account population size, confidence interval, 
and estimated proportion of the population with the 
outcome of interest [28], which in this case is viral sup-
pression. Assuming that 50% of adolescents had viral sup-
pression, a finite population size of 598, a design effect of 
1.4, and a 10% dropout or refusal rate, a minimum sample 
size of 310 was required for the study to measure varia-
bles among selected adolescents with a confidence inter-
val of 4.3%.
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Third, the number of participants recruited from each 
cluster was determined. Because the size of the ART clin-
ics varies, the probability proportional to size sampling 
method [28] was used in order to ensure that adolescents 
in larger sites have the same probability of being included 
in the sample as those in smaller sites. Cumulative popu-
lation size of each ART clinic was calculated, sampling 
interval was determined, and potential participants were 
randomly selected from the database using a random 
number table.
Finally, a list of selected adolescents was prepared and 
assigned with  a unique identification number based on 
the clinic identification (ID) code. The selected adoles-
cents were then contacted on the phone, screened for 
eligibility, and informed about the research objectives 
as well as place, date, and time of the interview by local 
study coordinators. Potential participants were included 
if they were aged between 15 and 17 years, receiving HIV 
care and treatment services from the selected ART clin-
ics, able to communicate in Khmer, allowed by a parent 
or guardian to participate, able to present themselves on 
the day of the interview, and physically and mentally sta-
ble to assent and participate in the study. Recruitment 
continued until the required sample size for each cluster 
was achieved.
Variables and measurements
In reference to existing literature [29, 30], a structured 
questionnaire was developed. Socio-demographic char-
acteristics included age, gender, schooling-related infor-
mation, parental and caregiver information, and social 
support the adolescents or their family had received 
for health care. Clinical and immunological data were 
obtained from medical records at the clinic. These 
included CD4 count and viral load at the enrolment in 
the clinic and the most recent test, duration of receiv-
ing HIV care and treatment, type of ART clinic (pediat-
ric or adult), current antiretroviral (ARV) regimen (first 
or second line), as well as ARV supply and arrangement. 
We also collected information on adolescents’ prefer-
ence, experience, and understanding in HIV care and 
treatment, HIV knowledge, coping strategies, and the 
maturity of the adolescents in dealing with HIV care and 
treatment.
Data collection training
Two teams of interviewers and coordinators were trained 
for two days on the study protocol, research ethics, confi-
dentiality, and interview techniques. Tool pretesting was 
conducted among 20 adolescents living with HIV in an 
ART clinic in Phnom Penh, followed by revisions of con-
tents and language based on feedback from the pre-test. 
Adolescents who participated in the pre-test were not 
included in the main study.
Data analyses
Epi Data version 3 (Odense, Denmark) was used for 
double data entry and coding. Descriptive analyses were 
conducted to determine proportions for categorical vari-
ables and means and standard deviation (SD) or median 
and interquartile range (IQR) for continuous variables. In 
accordance with the national guidelines [5], adolescents 
were categorized as having viral suppression if the viral 
load count was < 1000 ribonucleic acid (RNA) copies/mL 
at the latest viral load count, which differs from the defi-
nition used in  high-income settings [31]. We used Chi 
square test (or Fisher’s exact test when a cell count was 
smaller than five) for categorical variables and Student’s 
t-test or Mann–Whitney Test as appropriate for continu-
ous variables to compare variables among adolescents 
with and without viral suppression.
To identify factors associated with viral non-suppres-
sion, a multivariate logistic regression model was con-
structed. Age, gender, and all variables associated with 
viral non-suppression in bivariate analyses at a level of 
p-value < 0.05 were simultaneously included in the model, 
followed by a backward selection. p-values of < 0.05 were 
considered statistically significant. SPSS version 22 (IBM 
Corporation, New York, USA) was used for all statistical 
analyses.
Ethics statement
The National Ethics Committee for Health Research, 
Ministry of Health, in Cambodia approved the study pro-
tocol (Ref: 297NECHR). All participants were required 
to assent to the study, and a written informed consent 
from a parent or guardian was obtained before data col-
lection. Interviews were conducted in private locations, 
and confidentiality was strictly protected by removing all 
personal identifiers from the sampling frame, question-
naires, and field notes. Each participant was assigned a 
unique code. Researchers and data collectors were care-
fully trained on ethical issues. All participants were pro-




Socio-demographic characteristics of participants are 
shown in Table  1. This study included 328 adolescents 
living with HIV with a mean age of 15.9 (SD = 0.8); 
of whom, 48.5% were female. Less than half (42.7%) 
reported currently living with their biological parents, 
and 50.9% reported that their mother was alive. More 
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Table 1 Socio-demographic characteristics of adolescents living with HIV with and without viral suppression
ART antiretroviral therapy, CI confidence interval, HIV human immunodeficiency virus, NGO non-governmental organization
Socio‑demographic characteristics Total (n = 328)
n (%)
Latest viral load count





n (%) n (%)
Age group (in years)
 15 126 (38.4) 36 (47.4) 90 (35.7)
 16 107 (32.6) 25 (32.9) 82 (32.5)
 17 95 (29.0) 15 (19.7) 80 (31.7)
Male gender 169 (51.5) 38 (50.0) 131 (52.0)
Currently living with
 Parents 140 (42.7) 44 (57.9) 96 (38.1)
 Grandparents 49 (14.9) 15 (19.7) 34 (13.5)
 Relatives 106 (32.3) 11 (14.5) 95 (37.7)
 In an orphanage 27 (8.2) 4 (5.3) 23 (9.1)
 Other 6 (1.8) 2 (2.6) 4 (1.6)
Mother is still alive 167 (50.9) 33 (44.3) 134 (53.2)
Mother’s level of formal education
 Lower than high school 97 (29.6) 31 (40.8) 66 (26.2)
 High school or higher 61 (18.6) 12 (15.8) 49 (19.4)
 No mother/don’t know 170 (51.8) 33 (43.4) 137 (54.4)
Father is still alive 130 (39.6) 34 (44.7) 96 (38.1)
Father’s level of formal education
 Lower than high school 58 (17.7) 21 (27.6) 37 (14.7)
 High school or higher 68 (20.7) 13 (17.1) 55 (21.8)
 No father/don’t know 202 (61.6) 42 (55.3) 160 (63.5)
Main daily caregiver
 Parent 187 (57.0) 58 (76.3) 129 (51.2)
 Grand parent 5 (1.5) 1 (1.3) 4 (4.6)
 Sibling 24 (7.3) 3 (3.9) 21 (8.3)
 Relatives 100 (30.5) 11 (14.5) 89 (35.3)
 Orphanage/NGO staff 12 (3.7) 3 (3.9) 9 (3.6)
Main caregiver’s education lower than high school 54 (27.7) 11 (32.4) 43 (26.7)
Your level of formal education
 Primary school or lower 92 (28.0) 25 (32.9) 67 (26.6)
 Secondary school 168 (51.2) 37 (48.7) 131 (52.0)
 High school or higher 68 (20.7) 14 (18.4) 54 (21.4)
Currently attending school
 Not currently in school 55 (16.8) 16 (21.1) 39 (15.5)
 With disruption 75 (22.9) 18 (23.7) 57 (22.6)
 Fulltime 198 (60.4) 42 (55.3) 156 (61.9)
Family received social support 114 (34.8) 23 (30.3) 91 (36.1)
Belonged to a support group 97 (29.6) 16 (21.1) 81 (32.1)
Type of ART site
 Pediatric 225 (68.6) 36 (47.4) 189 (75.0)
 Adult 94 (28.7) 36 (47.4) 58 (23.0)
 Other 9 (2.7) 4 (5.3) 5 (2.0)
Receiving first line ARV regimen 271 (82.6) 63 (82.9) 208 (82.5)
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than half (57.0%) reported that their parent was their 
main caregiver. In general, level of education of their par-
ents was low, with less than half completing high school. 
Regarding their own education, 60.4% reported currently 
attending school full time, while 22.9% were in school 
but with interruption. About one-third (34.8%) reported 
that their family received social support for their health 
care, and 29.6% belonged to a patient support group. The 
majority (68.6%) were receiving HIV care and treatment 
from a pediatric ART clinic, and 82.6% were on first line 
ART regimen.
Compared to 15.8% among adolescents aged 17, 28.6% 
of adolescents aged 15 had a viral load ≥ 1000 RNA cop-
ies/mL (p = 0.03). Almost one-third (31.4%) of adoles-
cents living a biological parent had a viral load ≥ 1000 
RNA copies/mL compared to 10.4% among adolescents 
living with a relative (p < 0.001). Similarly, the proportion 
of adolescents having a viral load ≥ 1000 RNA copies/mL 
was significantly higher among adolescents having a par-
ent as the main caregiver compared to that among ado-
lescents having a relative as the main caregiver (31.0% vs. 
11.0%, p < 0.001). The proportion of adolescents having a 
viral load ≥ 1000 RNA copies/mL was also significantly 
higher among adolescents receiving HIV care in an adult 
clinic compared to that among adolescents receiving HIV 
care in a pediatric clinic (38.3% vs. 16.0%, p < 0.001).
Medical history
Table 2 shows that, on average, the adolescents had been 
in HIV care for 10.1 (interquartile range [IQR] = 8.0–
11.5) years and received ART for 8.6 (IQR = 6.0–10.6) 
years. Median CD4 count at the enrolment was 561 
(IQR = 274–798) and at the most recent test was 672 
(IQR = 483–827). Median viral load at the first test was 
628 RNA copies/mL (IQR = 315–3427) and at the most 
recent test was 215 RNA copies/mL (IQR = 168–2153). 
Compared to adolescents with viral suppression, adoles-
cents without viral suppression had received care services 
from an ART clinic (8.9  years vs. 10.4  years, p = 0.002) 
and been on ART (6.9 years vs. 9.2 years, p < 0.001) for a 
significantly shorter duration. Adolescents without viral 
suppression had significantly lower latest CD4 count (594 
vs. 699, p < 0.001) and higher first viral load count (7036 
RNA copies/mL vs. 312 RNA copies/mL, p < 0.001) than 
adolescents with viral suppression.
HIV knowledge
As shown in Table  3, HIV knowledge among adoles-
cents living with HIV in this study was generally good, 
although room remains for improvement. For example, 
42.1% of the participants agreed that there is a cure for 
AIDS. A considerable proportion of them believed that, 
if both partners are HIV-positive, they do not have to use 
a condom (38.1%); if people living with HIV take medi-
cines, they do not have to use a condom (26.2%), and it is 
okay for people living with HIV to miss their medicines 
(13.1%). The proportion of adolescents having a viral load 
≥ 1000 RNA copies/mL was significantly higher among 
adolescents who believed that there is a cure for AIDS 
compared to adolescents who did not believe this (33.3% 
vs. 13.9%, p < 0.001).
Understanding of HIV care and treatment
Table  4 shows that the majority (68.0%) of participants 
preferred to receive HIV care and treatment services 
from a pediatric ART clinic; 47.9% preferred to discuss 
questions related to health, sexual life, or daily life with 
their family members; 72.0% could recognize when they 
are getting sick; 88.7% were somewhat prepared or very 
prepared to manage their treatment going forward; 80.5% 
knew when they need to call a doctor; and 54.0% were 
responsible for refilling their own medicines. Regarding 
adherence to ART, 23.8% found it difficult to remember 
to take medicines; 11.0% would stop taking medicines 
when they feel worse; and 14.0% had missed medicines 
in the past 4 days. The proportion of adolescents having a 
Table 2 Medical history among adolescents living with HIV with and without viral suppression
Values are median (interquartile range)
ARV antiretroviral, ART antiretroviral therapy, HIV human immunodeficiency virus, RNA ribonucleic acid
Medical history Total (n = 328) Latest viral load count
≥ 1000 RNA copies/mL (n = 76) < 1000 RNA 
copies/mL 
(n = 252)
Time since first ART clinic visit (in years) 10.1 (8.0–11.5) 8.9 (5.2–10.4) 10.4 (8.8–11.7)
Time since ART initiation (in years) 8.6 (6.0–10.6) 6.9 (0.1–12.5) 9.2 (1.2–14.3)
CD4 count at enrolment 561 (274–798) 567 (271–710) 561 (277–825)
Latest CD4 count 672 (483–827) 594 (376–723) 699 (529–858)
First viral load count (RNA copies/mL) 628 (315–34,427) 7036 (426–93,625) 312 (218–630)
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viral load ≥ 1000 RNA copies/mL was significantly higher 
among adolescents who responded that they preferred to 
discuss issues related to health, sexual life, or daily life 
with their family members compared to adolescents who 
preferred to discuss these issues with health care provid-
ers (29.9% vs. 17.9%, p = 0.02).
Factors associated with viral non‑suppression
Table 5 shows factors associated with viral non-suppres-
sion in a multivariate logistic regression model. After 
controlling for the effect of other covariates, the likeli-
hood of having viral non-suppression remained sig-
nificantly lower among adolescents who were aged 17 
(AOR = 0.46, 95% CI 0.21–0.98), had been on ART for 
more than nine  years (AOR = 0.35, 95% CI 0.19–0.64), 
had most recent CD4 count of > 672 (AOR = 0.47, 
95% CI 0.26–0.86), had a relative as the main car-
egiver  (AOR = 0.37, 95% CI 0.17–0.80), and did not 
believe that there is a cure for AIDS (AOR = 0.40, 95% CI 
0.21–0.75) compared to their reference group. The like-
lihood of having viral non-suppression remained signifi-
cantly higher among adolescents who had first viral load 
> 628 RNA copies/mL (AOR = 1.81, 95% CI 1.05–4.08) 
and were receiving HIV care and treatment from an adult 
ART clinic (AOR = 2.95, 95% CI 1.56–5.59).
Discussion
After an average of 8.6 years on ART, the rate of viral sup-
pression among adolescents living with HIV in this study 
was considerably high at 76.8%. This observed level of 
viral suppression falls short of the UNAIDS’s 90–90–90 
global targets, but it is well within the range reported in 
other studies. In a recent  review, eight studies reported 
that the proportion of adolescents with viral suppres-
sion at 12 months ranged from 27 to 89% [32]. Another 
review that included 11 cohort studies also reported viral 
suppression rates between 28 and 78% [3]. Apart from 
reporting the proportion of adolescents with suppressed 
viral loads, the present study also identified independent 
predictors of viral non-suppression, which have impor-
tant implications for HIV clinical service delivery across 
the study sites.
Older  age  may predict viral suppression. This 
might be related to the increasing treatment experi-
ence among older long-term survivors as reported in 
other studies [33, 34]. In Cambodia, treatment regi-
men and formulations for people living with HIV aged 
over 14 years old are similar to that for adults as long 
as they weigh more than 35  kg [5]. Because adoles-
cence is characterized by increasing cognition [35–37], 
the relationship between viral suppression and age 
among long-term survivors of HIV could be mediated 
Table 3 Assessment of HIV knowledge among adolescents 
living with HIV with and without viral suppression
CI confidence interval, HIV human immunodeficiency virus, OR odds ratio
HIV knowledge Total (n = 328)
n (%)
Latest viral load count
≥ 1000 RNA 
copies/mL 
(n = 76)
< 1000 RNA 
copies/mL 
(n = 252)
n (%) n (%)
HIV is a virus that attacks a person’s immune system
 True 263 (80.2) 58 (76.3) 205 (81.3)
 False 44 (13.4) 11 (14.5) 33 (13.1)
 Don’t know 21 (6.4) 7 (9.2) 14 (5.6)
The cells of immune system that fight infections are called CD4 cells
 True 203 (61.9) 44 (57.9) 159 (63.1)
 False 22 (6.7) 4 (5.3) 18 (7.1)
 Don’t know 103 (31.4) 28 (36.8) 75 (29.8)
The amount of HIV in a person’s blood is called viral load
 True 160 (48.8) 35 (46.1) 125 (49.6)
 False 26 (7.9) 5 (6.6) 21 (8.3)
 Don’t know 142 (43.3) 36 (47.4) 106 (42.1)
There is a cure for AIDS
 True 138 (42.1) 46 (60.5) 92 (36.5)
 False 165 (50.3) 23 (30.3) 142 (56.3)
 Don’t know 25 (27.6) 7 (9.2) 18 (7.1)
You can tell a person has HIV by looking at him or her
 True 46 (14.0) 11 (14.5) 35 (13.9)
 False 269 (82.0) 63 (82.9) 206 (81.7)
 Don’t know 13 (4.0) 2 (2.6) 11 (4.0)
A person will stay healthy if their CD4 cells are high and their viral load 
is low
 True 284 (86.6) 68 (89.5) 216 (85.7)
 False 23 (7.0) 4 (5.3) 19 (7.5)
 Don’t know 21 (6.4) 4 (5.3) 17 (6.7)
Even though a person with HIV may feel healthy, the virus can still be 
damaging his or her immune system
 True 248 (75.9) 64 (84.2) 184 (73.0)
 False 65 (19.8) 10 (13.2) 55 (21.8)
 Don’t know 15 (4.6) 2 (2.6) 13 (5.2)
If both partners are HIV positive, they don’t have to use a condom
 True 125 (38.1) 34 (44.7) 91 (36.1)
 False 155 (47.3) 33 (44.3) 122 (48.4)
 Don’t know 48 (14.6) 9 (11.8) 39 (15.5)
If people living with HIV take medicines, they don’t have to use a 
condom
 True 86 (26.2) 20 (26.3) 66 (26.2)
 False 193 (58.8) 42 (55.3) 151 (59.9)
 Don’t know 49 (14.9) 14 (18.4) 35 (13.9)
It is okay for people living with HIV to miss their medicines
 True 43 (13.1) 13 (17.1) 30 (11.9)
 False 274 (83.5) 61 (80.3) 213 (84.5)
 Don’t know 11 (3.4) 2 (2.6) 9 (3.6)
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by the impact of self-efficacy and self-competency and 
risk-taking on ART adherence [3, 33]. Similar findings 
regarding age were also found in a study among people 
living with HIV in South Africa, whereby adolescents 
aged < 15 were more likely to have unsuppressed viral 
load (viral load > 400 RNA copies/mL) compared with 
older patients [38]. Indeed, studies have consistently 
reported that increasing age reduced odds of non-viral 
suppression in Uganda (≥ 1000 RNA copies/mL) [39] 
and in several countries across Europe (> 50 RNA cop-
ies/mL) [40].
Shorter duration on ART was associated with viral non-
suppression, which is to be expected given the destruc-
tion of CD4 cells resulting from high viral replication. 
Although the relationship between viral non-suppres-
sion, immunological responses, and duration on ART is 
not always consistent [41], similar findings were reported 
in a South African study, which reported that adolescents 
who had been on ART between six and 12 months were 
more likely to have viral non-suppression (viral load > 400 
RNA copies/mL) compared with those who had been on 
treatment longer [38]. In our study, a  lower viral load at 
the  time of  initial clinic enrollment also predicted viral 
suppression, which is in line with mechanisms of ART 
action [3].
Preference for receiving HIV care and treatment from 
a pediatric ART clinic predicted viral suppression. This 
could be because of the existing familiarity and ability 
of pediatric providers to provide appropriate counseling 
to young people in Cambodia. According to the national 
monitoring data, the majority of the Cambodian adoles-
cents living with HIV are perinatally infected [5], and this 
may lead to having close relationships and contacts with 
their pediatric providers. Previous studies in Cambodia 
have shown that adolescents highly value current rela-
tionships with pediatric health providers and do not trust 
adult providers to maintain confidentiality [24, 25].
We also found that the belief that there is no cure for 
AIDS predicted viral suppression. This could be an indi-
cation of the perception of the importance of ART, and 
Table 4 Understanding of HIV care and treatment among adolescents living with HIV with and without viral suppression
ART antiretroviral therapy, HIV human immunodeficiency virus
Understanding in HIV care and treatment Total (n = 328)
n (%)
Latest viral load count
≥ 1000 RNA copies/mL (n = 76) < 1000 RNA 
copies/mL 
(n = 252)
n (%) n (%)
Preference in receiving HIV care and treatment services
 Pediatric ART clinic 217 (66.2) 44 (57.9) 173 (68.7)
 Adult ART clinic 111 (38.8) 32 (42.1) 79 (31.3)
Preferred to discuss questions related to health, sexual life, or daily life with
 Health care providers 67 (20.4) 12 (15.8) 55 (21.8)
 Counselors/peer educators 19 (5.8) 5 (6.6) 14 (5.6)
 Friends 44 (13.4) 4 (5.3) 40 (15.9)
 Family 157 (47.9) 47 (61.8) 110 (43.7)
 Other 41 (12.5) 8 (10.5) 33 (13.1)
Could recognize when you are sick 236 (72.0) 177 (70.2) 59 (77.6)
Preparedness to manage your treatment going forward
 Very prepared 42 (12.8) 9 (11.8) 33 (13.1)
 Somewhat prepared 249 (75.9) 57 (75.0) 192 (76.2)
 Somewhat unprepared 21 (6.4) 9 (11.8) 12 (4.8)
 Very unprepared 16 (4.9) 1 (1.3) 15 (6.0)
Know when you need to call a doctor 264 (80.5) 58 (76.3) 206 (81.7)
Responsible for making appointments 151 (46.0) 28 (36.8) 123 (48.8)
Responsible for refilling own medicines 177 (54.0) 35 (46.1) 142 (56.3)
Feel comfortable asking questions 44 (13.4) 10 (13.2) 34 (13.5)
Difficult to remember to take medicines 78 (23.8) 12 (15.8) 66 (26.2)
Stop taking medicines when you feel better 2 (0.6) 0 (0.0) 2 (0.8)
Stop taking medicines when you feel worse 36 (11.0) 12 (15.8) 24 (9.5)
Have missed medicines in the past 4 days 46 (14.0) 13 (17.1) 33 (13.1)
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potentially the importance of adherence. It is also possi-
ble that this is a reflection of appropriate education and 
counseling, which may also reinforce adherence. Poor 
treatment literacy and comprehension of the benefits of 
ART as a curative intervention negatively affects adher-
ence [42].
Several implications emanate from findings in this 
study. First, better evaluation of adherence among the 
24.2% who were not virally suppressed is warranted. Sec-
ond, practical interventions are needed to strengthen 
adherence among this subsample. These interventions 
need to be tailored to the individual needs of each adoles-
cent, and a combination of multiple approaches may be 
necessary. For instance, focusing particularly on younger 
adolescents and adolescents in transition to adult clinic 
with a range of counseling and social support could 
improve their treatment outcomes. Data from this sam-
ple (published elsewhere) suggest that transition to adult 
clinic is an ongoing challenge [23].
Data from this study showed that more than 88.0% of 
the adolescents were somewhat prepared or very pre-
pared to manage their own treatment, which reflects 
the strong self-preparedness and self-reliance for tran-
sition. One of the challenges encountered for transi-
tion is the preparedness at the adult provider side. This 
could have an implication on the observation that  68.0% 
of adolescents preferred to receive services at a pedi-
atric ART clinic. Similarly, enhancing counseling and 
Table 5 Factors associated with viral non-suppression among adolescents living with HIV (n = 328)
Age, gender, and all variables associated with viral non-suppression at a level of p < 0.05 were simultaneously included in a multivariate logistic regression model
AOR adjusted odds ratio, ART antiretroviral therapy, CI confidence interval
a Viral load count of < 1000 RNA copies/mL
† Median value was used as a cutoff to categorize the variables
Variables in the model Viral non‑suppressiona
OR (95% CI) p‑value AOR (95% CI) p‑value†
Age group
 15 Reference Reference
 16 0.76 (0.42–1.38) 0.37 0.80 (0.40–1.57) 0.51
 17 0.47 (0.24–0.92) 0.03 0.46 (0.21–0.98) 0.04
Duration on ART † (years)
 ≤ 9 Reference Reference
 > 9 0.26 (0.15–0.45) < 0.001 0.35 (0.19–0.64) 0.001
Most recent CD4  count†
 ≤ 672 Reference Reference
 > 672 0.45 (0.26–0.77) 0.003 0.47 (0.26–0.86) 0.02
First viral  load†
 ≤ 628 RNA copies/mL Reference Reference
 > 628 RNA copies/mL 2.04 (1.04–2.50) 0.02 1.92 (1.02–4.42) 0.04
Main daily care giver
 Parent Reference Reference
 Grand parent 0.56 (0.06–5.08) 0.60 0.72 (0.06–6.10) 0.80
 Sibling 0.32 (0.09–0.11) 0.07 0.30 (0.07–1.18) 0.08
 Relatives 0.28 (0.14–0.55) < 0.001 0.37 (0.17–0.80) 0.01
 Orphanage/NGO staff 0.74 (0.19–2.84) 0.66 0.49 (0.10–2.32) 0.37
Receiving HIV care and treatment from:
 Pediatric ART clinic Reference Reference
 Adult ART clinic 3.26 (1.88–5.64) < 0.001 2.95 (1.56–5.59) 0.001
There is a cure for AIDS
 True Reference Reference
 False 0.32 (0.18–0.57) < 0.001 0.40 (0.21–0.75) 0.005
Receiving HIV care and treatment from:
 Pediatric ART clinic Reference Reference
 Adult ART clinic 3.26 (1.88–5.64) < 0.001 2.95 (1.56–5.59) 0.001
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treatment literacy to improve adolescents’ understand-
ing of the importance of ART and the currently incurable 
nature of HIV could improve adherence to the treatment 
and viral suppression. For younger adolescents, the edu-
cation and information could be reinforced with their 
main caregivers and themselves during routine patient 
support group sessions.
Study limitations
This study has a number of limitations, which should 
be taken into account while interpreting the above find-
ings. First,  due to the sampling strategy, the study only 
included adolescents who were currently on treat-
ment. Adolescents who were lost to follow-up were not 
included, which could have resulted in overestimat-
ing the rate of viral suppression. Longitudinal follow up 
with multiple assessments of viral load trends may pro-
vide a better picture of virological response compared 
to the single latest viral load measurement used in this 
study.  Second, the study relied on self-reported data, 
which may be affected by recall and social desirability 
bias [43]. Third, adolescents who accessed care from low 
volume sites providing care to less than 10 adolescents 
were excluded, which may bias the results given that vol-
ume of patients is a key determinant of provider com-
petency [44] and patient outcomes [45]. Finally, due to a 
lack of genotype data for the sample, exploration of viro-
logical failure was not possible.
Conclusions
The proportion of adolescents living with HIV in this 
study who had viral load < 1000 RNA copies/mL was 
relatively high at 76.8%. However, this proportion falls 
short of the UNAIDS’ 90% target for on-treatment viral 
suppression. Findings from this study indicate that pro-
grams targeting younger adolescents and adolescents in 
transition from pediatric to adult clinics with a range of 
interventions including psychosocial support and treat-
ment counseling could further improve viral suppression 
outcomes among this young population.
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